Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer
Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas
Nexavar Improves PFS In Phase III Trial
Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease
Ibrutinib Produces 68% Overall Response Rate in Phase II Trial
Researchers Uncover Tumors Sensitive to Chemotherapy
Researchers Find Genetic Alterations in Triple-Negative Cancers Following Treatment
Existing HER2 Drugs May Help More In Breast Cancer Treatment
Smoking Intensity and Markers Predict Cancer Aggressiveness
Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk
No Difference in Toxicity Between IMRT and PRT In Medicare Patients
NCI CTEP Approved Trials For the Month of January
FDA Expands Gleevec Indication For Children with Ph+ ALL
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Alec Kimmelman named director of Perlmutter Cancer Center, quickly replacing ousted Benjamin Neel
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
